As the world races to find a vaccine for COVID-19, our colleague Dr Cem Gun, an Emergency Medicine Physician at Acıbadem University Atakent Hospital, has bravely volunteered for the country’s first clinical trial. On 9 October, he was administered the first dose of a COVID-19 vaccine developed in China and approved for trial by the Health Institutes of Turkey, at a high-key milestone event.
On why he volunteered for this trial, Dr Cem Gun said, “As a healthcare worker, I fall into the high-risk group for COVID-19 infection. I decided to be vaccinated not only to protect myself but also my patients and loved ones. I made this decision with peace of mind as it is a controlled trial; it is currently in Phase 3, making it a tested and safe vaccine.”
The vaccine will be administered in two doses, and volunteers will be monitored on its effectiveness over a year.
The World Bank has approved US$12 billion in financing to help developing countries buy and distribute COVID-19 vaccines, tests and treatments, aiming to support the vaccination of up to 1 billion people.
Related Stories
-(9).png?sfvrsn=3a9bdc39_1)
IHH Malaysia Shares Ramadan Blessings with Local Communities
Throughout Ramadan, many of our hospitals in Malaysia reached out to underserved communities with meaningful acts of compassion—reflecting IHH Malaysia’s commitment to giving back and fostering stronger social bonds.
-(6).png?sfvrsn=2b9f1bd5_1)
IHH Singapore Partners Insurers to Champion Colorectal Health
IHH Healthcare Singapore collaborates with leading insurers to promote colorectal health and provide accessible healthcare solutions.
-(8).png?sfvrsn=c74356f2_1)
Gleneagles Hospital Mumbai Brings Quality Liver Care to Indore
Gleneagles Hospital Mumbai teams up with DNS Hospital to provide world-class liver care closer to home for residents in Indore.
Fortis Hospitals Win Prestigious Awards at 12th International Patient Safety Conference
From Data to Action! IHH Malaysia's Game-Changing Approach With New Operations Command Centre
